175 related articles for article (PubMed ID: 1574578)
1. Cellular kinetics, dosimetry, and radiobiology of alpha-particle radioimmunotherapy: induction of apoptosis.
Macklis RM; Lin JY; Beresford B; Atcher RW; Hines JJ; Humm JL
Radiat Res; 1992 May; 130(2):220-6. PubMed ID: 1574578
[TBL] [Abstract][Full Text] [Related]
2. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac.
Hartmann F; Horak EM; Garmestani K; Wu C; Brechbiel MW; Kozak RW; Tso J; Kosteiny SA; Gansow OA; Nelson DL
Cancer Res; 1994 Aug; 54(16):4362-70. PubMed ID: 8044783
[TBL] [Abstract][Full Text] [Related]
3. A model of cell inactivation by alpha-particle internal emitters.
Humm JL; Chin LM
Radiat Res; 1993 May; 134(2):143-50. PubMed ID: 8488249
[TBL] [Abstract][Full Text] [Related]
4. Microdosimetric analysis of alpha-particle-emitting targeted radiotherapeutics using histological images.
Akabani G; Kennel SJ; Zalutsky MR
J Nucl Med; 2003 May; 44(5):792-805. PubMed ID: 12732682
[TBL] [Abstract][Full Text] [Related]
5. In vitro cytotoxicity of low-dose-rate radioimmunotherapy by the alpha-emitting radioimmunoconjugate Thorium-227-DOTA-rituximab.
Dahle J; Krogh C; Melhus KB; Borrebaek J; Larsen RH; Kvinnsland Y
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):886-95. PubMed ID: 19679402
[TBL] [Abstract][Full Text] [Related]
6. Radiotoxicity of bismuth-213 bound to membranes of monolayer and spheroid cultures of tumor cells.
Kennel SJ; Stabin M; Roeske JC; Foote LJ; Lankford PK; Terzaghi-Howe M; Patterson H; Barkenbus J; Popp DM; Boll R; Mirzadeh S
Radiat Res; 1999 Mar; 151(3):244-56. PubMed ID: 10073661
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility of the human pathogenic fungi Cryptococcus neoformans and Histoplasma capsulatum to gamma-radiation versus radioimmunotherapy with alpha- and beta-emitting radioisotopes.
Dadachova E; Howell RW; Bryan RA; Frenkel A; Nosanchuk JD; Casadevall A
J Nucl Med; 2004 Feb; 45(2):313-20. PubMed ID: 14960655
[TBL] [Abstract][Full Text] [Related]
8. Effective alpha-particle-mediated radioimmunotherapy of murine leukemia.
Huneke RB; Pippin CG; Squire RA; Brechbiel MW; Gansow OA; Strand M
Cancer Res; 1992 Oct; 52(20):5818-20. PubMed ID: 1394209
[TBL] [Abstract][Full Text] [Related]
9. Radioimmunotherapy with alpha-particle emitting radionuclides.
Zalutsky MR; Pozzi OR
Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):289-96. PubMed ID: 15640792
[TBL] [Abstract][Full Text] [Related]
10. The promise of targeted {alpha}-particle therapy.
Mulford DA; Scheinberg DA; Jurcic JG
J Nucl Med; 2005 Jan; 46 Suppl 1():199S-204S. PubMed ID: 15653670
[TBL] [Abstract][Full Text] [Related]
11. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
12. Validation of 213Bi-alpha radioimmunotherapy for multiple myeloma.
Couturier O; Faivre-Chauvet A; Filippovich IV; Thédrez P; Saï-Maurel C; Bardiès M; Mishra AK; Gauvrit M; Blain G; Apostolidis C; Molinet R; Abbe JC; Bataille R; Wijdenes J; Chatal JF; Chérel M
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3165s-3170s. PubMed ID: 10541359
[TBL] [Abstract][Full Text] [Related]
13. ²¹³Bi-anti-EGFR radioimmunoconjugates and X-ray irradiation trigger different cell death pathways in squamous cell carcinoma cells.
Pickhard A; Piontek G; Seidl C; Kopping S; Blechert B; Mißlbeck M; Brockhoff G; Bruchertseifer F; Morgenstern A; Essler M
Nucl Med Biol; 2014 Jan; 41(1):68-76. PubMed ID: 24210808
[TBL] [Abstract][Full Text] [Related]
14. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters.
Behr TM; Sgouros G; Stabin MG; Béhé M; Angerstein C; Blumenthal RD; Apostolidis C; Molinet R; Sharkey RM; Koch L; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3031s-3043s. PubMed ID: 10541340
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.
Elgqvist J; Andersson H; Bäck T; Hultborn R; Jensen H; Karlsson B; Lindegren S; Palm S; Warnhammar E; Jacobsson L
J Nucl Med; 2005 Nov; 46(11):1907-15. PubMed ID: 16269606
[TBL] [Abstract][Full Text] [Related]
16. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate.
Berndorff D; Borkowski S; Sieger S; Rother A; Friebe M; Viti F; Hilger CS; Cyr JE; Dinkelborg LM
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7053s-7063s. PubMed ID: 16203802
[TBL] [Abstract][Full Text] [Related]
17. [Alpha-radioimmunotherapy: a review of recent developments].
Supiot S; Thillays F; Rio E; Mahé MA; Barbet FJ; Kraeber-Bodéré F; Chérel M
Cancer Radiother; 2007 Sep; 11(5):252-9. PubMed ID: 17604673
[TBL] [Abstract][Full Text] [Related]
18. Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates.
Zalutsky MR; Bigner DD
Acta Oncol; 1996; 35(3):373-9. PubMed ID: 8679269
[TBL] [Abstract][Full Text] [Related]
19. Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody.
Yao Z; Garmestani K; Wong KJ; Park LS; Dadachova E; Yordanov A; Waldmann TA; Eckelman WC; Paik CH; Carrasquillo JA
J Nucl Med; 2001 Oct; 42(10):1538-44. PubMed ID: 11585870
[TBL] [Abstract][Full Text] [Related]
20. Radioimmunotherapy with α-particle-emitting radionuclides.
Seidl C
Immunotherapy; 2014; 6(4):431-58. PubMed ID: 24815783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
